PTPN11 mutations define a rare but highly adverse subset of myelodysplastic syndromes
Not available.
Saved in:
Main Authors: | Alexandre Bazinet, Alex Bataller, Guillermo Montalban-Bravo, Kelly Chien, Koji Sasaki, Wei Ying Jen, Mahesh Swaminathan, Tapan Kadia, Courtney DiNardo, Farhad Ravandi, Guillermo Garcia-Manero, Hagop Kantarjian |
---|---|
Format: | Article |
Language: | English |
Published: |
Ferrata Storti Foundation
2025-07-01
|
Series: | Haematologica |
Online Access: | https://haematologica.org/article/view/12158 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lower-intensity chemo-immunotherapy with cladribine, low-dose cytarabine, venetoclax and blinatumomab produces high response rates in patients with <i>BCR::ABL1</i>-negative B-cell / myeloid mixed phenotype acute leukemia
by: Roberta S. Azevedo, et al.
Published: (2025-06-01) -
Understanding infectious complications in patients with lower risk myelodysplastic syndromes: a step towards improving survival
by: Guillermo Garcia-Manero
Published: (2025-06-01) -
Study of myelodysplastic features in patients with myelodysplastic syndromes by multicolor flow cytometry
by: O. Yu. Davydova, et al.
Published: (2019-01-01) -
MYELODYSPLASTIC/MYELOPROLIFERATIVE DISEASES
by: I. N. Subortseva, et al.
Published: (2017-01-01) -
Deep Dive into Targeted Therapies: Understanding IDH1-Mutant AML Treatments [Podcast]
by: Zeidan AM, et al.
Published: (2025-07-01)